Evidence map›Paper›PMID 42505231›Full record

ArticleCurrent oncology (Toronto, Ont.)2026

Management of Acute Myeloid Leukemia in Older Patients: An Updated Canadian Consensus.

Andre C Schuh, Nicholas Chornenki, Mohamed A Elemary, Mahmoud Elsawy, Brett L Houston, Brian Leber, Lee Mozessohn, Mitchell Sabloff, Brittany Salter, David Sanford and 1 more

Abstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Andre C SchuhDepartments of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Nicholas ChornenkiDivision of Hematology, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.
Mohamed A ElemarySaskatoon Cancer Centre, Saskatoon, SK S7N 4H4, Canada.ORCID 0000-0002-7622-4065
Mahmoud ElsawyDivision of Hematology and Hematologic Oncology, Department of Medicine, Dalhousie University, Halifax, NS B3H 2Y9, Canada.
Brett L HoustonDepartment of Internal Medicine, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB R3E 3P5, Canada.ORCID 0000-0002-8776-4083
Brian LeberDepartment of Medicine, McMaster University, Hamilton, ON L8S 4L8, Canada.ORCID 0000-0001-5502-1480
Lee MozessohnSunnybrook Odette Cancer Centre, Toronto, ON M4N 3M5, Canada.
Mitchell SabloffDivision of Hematology, Department of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada.ORCID 0000-0002-0122-6138
Brittany SalterDepartment of Oncology, McMaster University, Hamilton, ON L8S 4L8, Canada.
David SanfordDivision of Hematology, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.
Joseph BrandweinDivision of Hematology, Department of Medicine, University of Alberta, Edmonton, AB T6G 2G3, Canada.ORCID 0000-0001-9095-8789

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

These are the third Canadian consensus guidelines on the management of acute myeloid leukemia (AML) in older patients. The first was published in 2013, and the second in 2017. The management of AML in older patients changed significantly over this time span, with decreasing emphasis on the use of intensive chemotherapy and the adoption of new standards of care based on less-intensive therapies: first azacitidine + venetoclax combinations, followed by azacitidine + ivosidenib. Increased use of these new therapies in older patients has raised questions about their use, including how to determine patient suitability, select the most effective therapy, and manage dosing and toxicity. In this third Canadian guideline, we address these questions to provide clarity around these new standards of care and improve clinician understanding and confidence in using them. As more new targeted agents become available and hypomethylating agent-based triplet combinations are used more widely, we fully anticipate that we will, in some years' time, write a fourth guideline on the management of AML in older patients.

Indexed as

Leukemia, Myeloid, AcuteAgedAntineoplastic Combined Chemotherapy ProtocolsAzacitidineCanadaHumansSulfonamidesAzacitidineSulfonamidesacute myeloid leukemiafitness assessmentivosidenibless-intensive treatmentolder patientsvenetoclax

Identifiers

PMID42505231
PMCPMC13409292

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.